ZURICH, April 21 Swiss biotechnology firm Actelion on Thursday upped its 2016 guidance on the back of a strong start for its new pulmonary arterial hypertension (PAH) medicine Uptravi.
Europe's biggest biotech firm raised its outlook for core operating income to grow at a high single-digit percentage rate from a low single-digit percentage range previously. Actelion reported first-quarter core operating income of 249 million Swiss francs ($256.4 million), up 8 percent year on year...
15:11 Apple's Most Popular Apps of 201612
10:05 JPMorgan, HSBC, Credit Agricole Fined $521 Million Over Euribor16
06:10 Sources: Carlos Gomez, Rangers agree on 1-year, $11.5 million deal16
20:33 The Late David Bowie Was Just Nominated For British Artist Of The Year At The 2016 BBC Music Awards!14